Proof-of-principle of a technology transfer of a dried blood virus neutralisation assay to a Gavi-eligible country.

ABSTRACT:

Background

Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income countries (LMICs) face barriers to participate, including lack of financial and human capacity and lack of research environment. Respiratory syncytial virus (RSV) vaccine development is also led by HICs, while LMICs carry the burden of life-threatening disease. Representative trials and research capacity strengthening in LMICs are needed to ensure global vaccine access and equity. This study aims to transfer an RSV neutralisation assay, which uses live cells and virus with inherent high variation, to a country eligible to receive support from the Gavi, the Vaccine Alliance.

Methods

Using a train-the-trainer approach, a Ghanaian researcher was trained in the Ne

SUBMITTER: Obodai E 

PROVIDER: S-EPMC11881193 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature